DGAP-News: Update: EDMOND DE ROTHSCHILD INVESTMENT PARTNERS

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
DGAP-News: Update: EDMOND DE ROTHSCHILD INVESTMENT PARTNERS SELLS ITS PARTICIPATION IN SAPIENS STEERING BRAIN STIMULATION, DEVELOPER OF DEEP BRAIN STIMULATION SOLUTIONS TO MEDTRONIC

DGAP-News: Edmond de Rothschild Investment Partners / Key word(s): Investment Update: EDMOND DE ROTHSCHILD INVESTMENT PARTNERS SELLS ITS PARTICIPATION IN SAPIENS STEERING BRAIN STIMULATION, DEVELOPER OF DEEP BRAIN STIMULATION SOLUTIONS TO MEDTRONIC 26.08.2014 / 13:09 --------------------------------------------------------------------- EDMOND DE ROTHSCHILD INVESTMENT PARTNERS SELLS ITS PARTICIPATION IN SAPIENS STEERING BRAIN STIMULATION, DEVELOPER OF DEEP BRAIN STIMULATION SOLUTIONS TO MEDTRONIC This operation is the sixth trade sale of BioDiscovery 3, the fourteenth from the BioDiscovery funds Edmond De Rothschild Investment Partners (EdRIP) announced today that its BioDiscovery 3 portfolio company, Sapiens Steering Brain Stimulation (Sapiens SBS) a privately held developer of deep brain stimulation (DBS) technologies, has been acquired by Medtronic, Inc. (NYSE: MDT) for approximately $200 million in an all-cash transaction. Sapiens SBS, located in Eindhoven, The Netherlands, is developing a DBS system that features an advanced DBS lead with 40 individual stimulation points. This advanced system is designed to allow more precise stimulation of the intended target in the brain and may potentially result in reduced procedure time and fewer stimulation-induced side effects. Employees at the Eindhoven facility will continue to work toward bringing this technology to market. In the future, the site will serve as a global research and development center for Medtronic's Neuromodulation business, complementing its existing R&D operations. Medtronic and Sapiens SBS will work to finalize product development and begin clinical research to integrate these technologies into an expanded portfolio of DBS products within Medtronic's Neuromodulation business. EdRIP co-led the series A round of Sapiens SBS as a spin-off from Philips Healthcare in 2011 to back the founders Sjaak Deckers, Hubert Martens and Michel Decre who believed that a much better resolution of the applied current in deep brain stimulation (DBS), could significantly improve the therapeutic window of DBS. In a very short time frame, Sapiens confirmed its initial hypothesis in acute human trials in Parkinson patients and became a clear leader in developing significantly improved devices for DBS therapeutic applications. In 2013, medtech veteran Jan Keltjens became the company's CEO and under his leadership the product was further advanced and refined. "Since 2011, Sapiens SBS employees have worked tirelessly to develop an advanced deep brain stimulation system," said Jan Keltjens, chief executive officer at Sapiens SBS. "We are excited to join Medtronic, and look forward to collectively working to bring this and other novel technologies and therapies to neuromodulation patients worldwide that could benefit from them." "In only about 3 years, Sapiens SBS has achieved a lot. Also, the way founders, management, board and investors have worked together in this company is, in my opinion, quite exceptional. Through this trade sale, in addition to making good return for our Limited Partners, it is very satisfying to see now the Sapiens' products integrated into the neurostimulation franchise of the DBS market leader, as it gives this technology the best chances of helping patients in the near future" says Olivier Litzka, Partner at EdRIP. Sapiens was the thirteenth investment of BioDiscovery 3, a specialized life science investment fund managed by Edmond de Rothschild Investment Partners. Raised in 2008, the Fund has invested from 2008 to 2012 in a portfolio of 14 companies. So far six of these companies have been sold through private transactions and two have been listed on public financial markets. About Edmond de Rothschild Investment Partners Edmond de Rothschild Investment Partners is the private equity affiliate of the Edmond de Rothschild Group, which is specialized in asset management and private banking (EUR 133.6bn under management, nearly 2,800 employees spread across 31 offices, branches and subsidiaries throughout the world). Founded in 1953, the Group has been chaired since 1997 by Baron Benjamin de Rothschild. Paris-based Edmond de Rothschild Investment Partners is dedicated to minority investments into privately-owned companies. It currently has more than EUR1 billion under management which is being invested primarily as life sciences venture capital and growth capital. Within Edmond de Rothschild Investment Partners, its Life Sciences Team of eight professionals brings together over 60 years of experience in the Life Science industry and more than 100 years of private equity and venture capital experience. The Team has raised EUR450 million through its Biodiscovery franchise and is currently investing BioDiscovery 4. Since inception, BioDiscovery Funds have invested in 49 companies, of which 13 have been sold and 12 listed on public financial markets. 19 are still active in the portfolios. BioDiscovery Funds, including BioDiscovery 4, are venture capital funds dedicated to professional investors. These funds are not authorized by the Autorité des Marchés Financiers and may adopt special investment rules. For more information : www.edrip.fr Contacts Edmond de Rothschild Investment Partners Olivier Litzka o.litzka@edr.com Tel: +33 1 40 17 27 46 --------------------------------------------------------------------- 26.08.2014 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- 283955 26.08.2014

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Grupo Simec 2026 Nine-Month Financial Surge Spells Change

Updated Category News Views 64

Sharp Climb in Net Income Sparks Interest Buckle up, folks. Grupo Simec's nine-month results for 2026 are a mixed bag of surprises and steady flows. Let’s break it down: the net income skyrocketed by a whopping 428% compared to the same period last year—jumping from Ps. 763 million to Ps. 4,028 million. That's a solid leap, and it’s largely due to turning a hefty...

Continue Reading
Cloopen Group's Private Transition: What Investors Should Know

Updated Category News Views 121

Cloopen Steps Away from Public Market Scene Here's a tale simmering on the corporate backburner: Cloopen Group Holding Limited, that cloud juggernaut over in China, has gone all private on us. The ink is drying on their merger with SummerX Holdings Limited, under the overarching umbrella of SpringX Holdings. So, now this communications outfit has slipped out of the public...

Continue Reading
LanguageLine AI App Earns Vizient Technology Kudos

Updated Category News Views 0

Tech Talk: LanguageLine's AI App Gains Important Recognition Diving headfirst into the chaotic world of healthcare, LanguageLine's AI Translation App earned a standout accolade. Just announced, it's snagged the Innovative Technology Designation from Vizient, the heavyweight champ in healthcare performance improvement. On the scene since the end of October, they rolled the...

Continue Reading
Core Lab's Quarterly Grit: Navigating a Turbulent Market

Updated Category News Views 71

Core Lab's Quarter in Review With the kind of resilience that makes a trader's hands shake ever so slightly less over a coffee, Core Laboratories Inc. heads into the fourth quarter of 2026. This isn't your typical Wall Street story, that's for sure. Watching a solid player like Core navigate the bumpy roads of today's volatile market reminds me of a...

Continue Reading
Freddy’s Joins Hershey For a Limited-Time Flavor Fest

Updated Category News Views 95

The Sweet Collaboration We Didn't See Coming Well, folks, here's a tasty twist for you—Freddy's Frozen Custard & Steakburgers is cozying up to The Hershey Company to bring a sugar rush to our mundane lives. Starting Nov. 4, they're rolling out a limited-time series of treats so indulgent you'll want to skip straight to dessert. And if that wasn't enough, they're...

Continue Reading
Bloomberg Law Integrates Docket Data with AI Platform

Updated Category News Views 0

Bloomberg Law's Game-Changer for Legal Pros Here's something that'll make legal eagles perk up on this fine day: Bloomberg Law has rolled out a connector for Claude, marrying court dockets and litigation smarts to AI. Let's face it, the legal world always runs on precision and timing above all. So when an integration like this drops, it ain’t just a memo on the office...

Continue Reading
AppLovin Faces Class Action: AI Growth Claims Under Fire

Updated Category News Views 67

AppLovin's AI Jackpot: A Busted Flush? This year's been a rollercoaster at AppLovin Corporation, and not the fun kind. Let me tell ya, investors bought into a dream—a self-sustaining, profit-churning machine based on AI advertising models. Unfortunately, reality came around like a bad penny, and suddenly, their 'virtuous cycle' feels more like a busted flush....

Continue Reading
Genedata's New ELN Transforms Biopharma R&D Workflows

Updated Category News Views 58

Revolutionizing Research with a New Digital Tool Genedata, the brain behind enterprise software for drug discovery, has thrown a curveball into the world of biopharmaceutical research by launching a pioneering electronic lab notebook (ELN). This isn’t just another software update; it's a complete shift in how R&D workflows are structured and maintained. With an...

Continue Reading
J.H. Strain & Sons' Asset Sale Seals a New Era

Updated Category News Views 59

Texan Legacy Bows Out of the Asphalt Game Here's a fresh chapter in the world of road construction that'll have folks in the industry doing a double-take. Elder Bray & Bankler, a bigwig among corporate law circles, has been guiding this tale. They've shepherded J.H. Strain & Sons through selling off its asphalt manufacturing and construction assets to none other than...

Continue Reading
Motiva's Q3 2026 Results: Strategic Moves Drive Growth

Updated Category News Views 0

Strategic Transactions and Financial Highlights Motiva's third quarter of 2026 shows a company not just coasting but recalibrating its trajectory. Big moves had ripple effects on their financial landscape, most notably their sale of the Airport Platform, concluded for a hefty R$5.2 billion. Their portfolio's trimming isn't just a garage sale but a thought-out step...

Continue Reading

Top 5 Most Recently Viewed Articles

Lilly Flexes Oncology Muscle at 2026 ASCO Meet

Updated Category News Views 19

Lilly's Pipeline Gets the Spotlight With the ASCO conference kicking off in Chicago this year, Eli Lilly (NYSE: LLY) is coming in guns blazing. The company's oncology roster is vast and spread across a variety of tumor types and treatment modalities. This year's presentations are dripping with promise. You got Retevmo leading the charge in a plenary session, joined by...

Continue Reading
David Brenneman Strengthens Antitrust Practice at Latham

Updated Category News Views 212

David Brenneman Joins Latham & Watkins Latham & Watkins LLP is excited to announce a significant addition to their Antitrust & Competition Practice. Renowned antitrust lawyer David Brenneman has joined their Washington, D.C. office as a partner. Brenneman brings considerable expertise in managing the antitrust aspects of various mergers and acquisitions, enhancing the...

Continue Reading
Join the Class Action for Viatris Inc.: Important Updates

Updated Category News Views 419

Understanding the Viatris Class Action Opportunity Attention, investors! If you've purchased securities of Viatris Inc. (NASDAQ: VTRS), this is a critical time for you. The Rosen Law Firm, renowned for advocating investor rights globally, is reaching out to individuals who bought Viatris stocks during an identified time frame. Having knowledge of these events is essential...

Continue Reading
Transformative Health Education: Empowering Future Generations

Updated Category News Views 120

Understanding the Growing Health Crisis A crisis is quietly unfolding in classrooms across the nation: rising rates of preventable chronic illnesses, mental health struggles, and pervasive health illiteracy are significantly impacting the wellness of today's youth. In the face of these alarming statistics, Know Yourself Academy emerges as a beacon of hope, aiming to...

Continue Reading
Free Guide by Pacific Mind Health Eases Anxiety

Updated Category News Views 11

Wrestling with Your Inner Spotlight? Pacific Mind Health Steps In There's a good chance most of us have been there—sweatin' the small stuff like we're the star attraction in the circus of life, convinced everyone else is watching as we trip over our own shoelaces. Well, don't sweat it. Pacific Mind Health has jumped in to lend a hand with some real tools to shake off...

Continue Reading